Novel Innate Immune Adjuvant for Avian Influenza. West Nile Virus, and ZIKA Vaccines

用于禽流感的新型先天免疫佐剂。

• 批准号: 9543270
• 负责人: MICHAEL GALE
• 金额: $ 330.8万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-30 至 2018-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9543270
• 关键词: Adjuvant; Adjuvant Study; Antigens; Avian Influenza; Avian Influenza A Virus; Bird Flu vaccine; Development; Dose; Emerging Communicable Diseases; FDA approved; Ferrets; Flavivirus; Formulation; Genes; Human; IRF3 gene; Immunologic Adjuvants; Immunologics; Infection; Influenza A Virus, H5N1 Subtype; Investigation; Investigational Drugs; Investigational New Drug Application; Lead; Licensure; Mus; National Institute of Allergy and Infectious Disease; Natural Immunity; Pathogenicity; Pathway interactions; Pharmaceutical Chemistry; Program Development; System; Toxicology; Tretinoin; Vaccine Adjuvant; Vaccines; Virus Diseases; West Nile virus; Zika virus vaccine; adaptive immune response; novel; pathogen; programs; response; small molecule; transcription factor; vaccine candidate

The NIAID/DAIT Adjuvant Development Program supports the development of new candidate vaccine adjuvants through immunological characterization studies and lead compound optimization, up to and including IND-enabling studies, all towards licensure for human use. Adjuvants will be studied with currently licensed or new investigational vaccines to protect against infection by NIAID emerging and re-emerging infectious disease pathogens.

NIAID/DAIT辅助开发计划通过免疫特征研究和铅复合优化（直至辅助研究）来支持新的候选疫苗佐剂的开发，所有这些佐剂都旨在获得人使用的许可。将对目前有执照或新的研究疫苗进行研究，以防止NIAID新兴和重新出现感染性疾病病原体感染。